Silk Road Medical, Inc (NASDAQ:SILK) Holdings Decreased by Macquarie Group Ltd.

Macquarie Group Ltd. trimmed its position in Silk Road Medical, Inc (NASDAQ:SILK) by 52.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,966 shares of the company’s stock after selling 64,115 shares during the quarter. Macquarie Group Ltd. owned approximately 0.15% of Silk Road Medical worth $2,268,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in SILK. PNC Financial Services Group Inc. increased its holdings in shares of Silk Road Medical by 91.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 466 shares of the company’s stock valued at $25,000 after acquiring an additional 222 shares during the last quarter. Quarry LP boosted its position in Silk Road Medical by 535.1% during the 1st quarter. Quarry LP now owns 978 shares of the company’s stock valued at $38,000 after purchasing an additional 824 shares during the period. US Bancorp DE boosted its position in Silk Road Medical by 41.3% during the 1st quarter. US Bancorp DE now owns 1,673 shares of the company’s stock valued at $69,000 after purchasing an additional 489 shares during the period. Wells Fargo & Company MN boosted its position in Silk Road Medical by 12.9% during the 4th quarter. Wells Fargo & Company MN now owns 1,829 shares of the company’s stock valued at $97,000 after purchasing an additional 209 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in Silk Road Medical by 154.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,187 shares of the company’s stock valued at $143,000 after purchasing an additional 1,934 shares during the period.

Insider Transactions at Silk Road Medical

In other news, CEO Erica J. Rogers sold 1,000 shares of the business’s stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $31.56, for a total transaction of $31,560.00. Following the sale, the chief executive officer now directly owns 269,639 shares of the company’s stock, valued at $8,509,806.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Erica J. Rogers sold 1,000 shares of the company’s stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $31.56, for a total transaction of $31,560.00. Following the transaction, the chief executive officer now directly owns 269,639 shares of the company’s stock, valued at $8,509,806.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kevin M. Klemz sold 1,539 shares of the firm’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $20.11, for a total value of $30,949.29. Following the sale, the executive vice president now owns 38,797 shares of the company’s stock, valued at $780,207.67. The disclosure for this sale can be found here. Insiders have sold 9,195 shares of company stock valued at $210,404 over the last three months. Company insiders own 6.70% of the company’s stock.

Silk Road Medical Trading Down 2.4 %

Shares of Silk Road Medical stock opened at $16.52 on Tuesday. The company has a quick ratio of 8.90, a current ratio of 9.69 and a debt-to-equity ratio of 0.48. The firm has a market cap of $641.47 million, a price-to-earnings ratio of -11.72 and a beta of 1.16. The business has a fifty day simple moving average of $20.67 and a 200-day simple moving average of $31.47. Silk Road Medical, Inc has a fifty-two week low of $16.20 and a fifty-two week high of $58.04.

Silk Road Medical (NASDAQ:SILK) last announced its quarterly earnings data on Tuesday, August 1st. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.04. The business had revenue of $45.30 million during the quarter, compared to analyst estimates of $43.32 million. Silk Road Medical had a negative return on equity of 40.05% and a negative net margin of 32.83%. On average, equities analysts forecast that Silk Road Medical, Inc will post -1.46 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Citigroup reduced their price objective on Silk Road Medical from $48.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, August 14th. B. Riley reduced their price objective on Silk Road Medical from $58.00 to $54.00 and set a “buy” rating for the company in a research report on Wednesday, August 2nd. Argus reduced their price target on Silk Road Medical from $70.00 to $55.00 in a research report on Monday, May 22nd. Oppenheimer began coverage on Silk Road Medical in a research report on Tuesday, September 5th. They set an “outperform” rating and a $30.00 price target for the company. Finally, Wolfe Research reduced their price target on Silk Road Medical from $27.00 to $13.00 in a research report on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. According to MarketBeat, Silk Road Medical has a consensus rating of “Hold” and a consensus target price of $37.60.

About Silk Road Medical

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a specialty balloon for the TCAR procedure.